Horizon Pharma plc (HZNP) Shares are Down -14.86%

Horizon Pharma plc (HZNP) has risen sharply, recording gains of 0.73% in the past 4 weeks. However, the stock has corrected -14.86% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.94% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 9.18% and the fifty day Moving Average is 0.78%. Horizon Pharma plc is up 17.05% in the last three month period. Year-to-Date the stock performance stands at -10.34%.

Horizon Pharma plc (HZNP) : Average target price received by Horizon Pharma plc (HZNP) is $32.29 with an expected standard deviation of $8.46. The most aggressive target on the stock is $45, whereas the most downbeat target is $24. 7 financial analysts are currently covering the stock.


Horizon Pharma plc (NASDAQ:HZNP): stock turned positive on Friday. Though the stock opened at $19.17, the bulls momentum made the stock top out at $19.515 level for the day. The stock recorded a low of $19.05 and closed the trading day at $19.43, in the green by 1.30%. The total traded volume for the day was 5,596,262. The stock had closed at $19.18 in the previous days trading.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.